Acute respiratory distress syndrome (ARDS) results in catastrophic lung failure and has an urgent, unmet need for improved early recognition and therapeutic development. Neutrophil influx is a hallmark of ARDS and is associated with the release of tissue-destructive immune effectors, such neutrophil transmigration. In mouse pneumonia models, both genetic deletion and pharmacologic containment. Unexpectedly, the alterations of neutrophil function were not attributable to impaired disease severity. We propose that in acute inflammatory lung diseases such as pneumonia and ARDS, ADAM8 inhibition might allow fine-tuning of neutrophil responses for therapeutic gain.
原文链接
分享
引用
